Evidence map›Paper›PMID 41266010›Full record

ReviewClinics in liver disease2026

Disease Modulating Agents in Cirrhosis.

Vinay Jahagirdar, Jasmohan Singh Bajaj

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinics in liver disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Vinay JahagirdarDivision of Gastroenterology, Hepatology & Nutrition, Department of Internal Medicine, Virginia Commonwealth University, 1200 East Broad Street, 14th Floor, Box 980341, Richmond, VA 23298, USA.
Jasmohan Singh BajajDivision of Gastroenterology, Hepatology & Nutrition, Department of Internal Medicine, Virginia Commonwealth University, 1200 Broad Rock Boulevard, Richmond, VA 23249, USA. Electronic address: jasmohan.bajaj@vcuhealth.org.

Funding

Fecal microbiota transplant for Alcohol-Associated CirrhosisR01AA029398 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Jasmohan S Bajaj, ALEXANDER KHORUTS · 2022 to 2026
$2.9M
Liver Cirrhosis Network: Clinical Research CentersU01DK130134 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI Jasmohan S Bajaj, ARUN J SANYAL · 2021 to 2026
$2.0M
Evaluation of individual FMT as a potential therapeutic to reduce ethanol drinking in miceR21AA031293 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI BAJAJ, JASMOHAN S, WOLSTENHOLME, JENNIFER T · 2024 to 2025
$408k
CSRD VA I01 CX002472CSRD VA I01 CX002863NIAAA NIH HHS R01 AA029398NIAAA NIH HHS R21 AA031293NIDDK NIH HHS U01 DK130134
6 · The paper itself

Abstract

The article discusses the progression and management of cirrhosis, emphasizing the importance of precise disease staging from compensated to decompensated states. This article evaluates the roles of beta-blockers, albumin, and rifaximin, emphasizing their potential as disease-modulating agents. By exploring these therapeutic strategies within clinical and research frameworks, the article reinforces the necessity for innovative treatments that can fundamentally alter the natural course of cirrhosis and improve patient outcomes.

Indexed as

Adrenergic beta-AntagonistsAlbuminsLiver CirrhosisRifamycinsDisease ProgressionHumansRifaximinAdrenergic beta-AntagonistsAlbuminsRifamycinsRifaximinAlbuminBeta-blockersCirrhosisDecompensationPortal hypertensionRifaximinStatins

Identifiers

PMID41266010
PMCPMC13508001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.